[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340768-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340768-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeted-crisprcas9-lipid-nanoparticles-elicits-therapeutic-genome-editing-in-head-and-neck-cancer","Targeted CRISPR/Cas9 Lipid Nanoparticles Elicits Therapeutic Genome Editing in Head and Neck Cancer","","Head and neck squamous cell carcinomas (HNSCC) are driven by aggressive local growth and frequently recur after standard multimodal therapy, leading to poor survival. Building on mRNA and lipid nanoparticle (LNP) platforms, the study presents an intratumoral EGFR-targeted CRISPR-LNP approach designed to knock out SOX2, a cancer-specific gene. Ionizable-lipid LNPs co-encapsulating Cas9 mRNA and sgSOX2 reduce HNSCC cell viability by about 60% in vitro. In xenograft models, EGFR-targeted delivery inhibits tumor growth by 90% and increases survival by 90% for over 84 days, with tumor disappearance in half of animals.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeted-crisprcas9-lipid-nanoparticles-elicits-therapeutic-genome-editing-in-head-and-neck-cancer/340768/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeted-crisprcas9-lipid-nanoparticles-elicits-therapeutic-genome-editing-in-head-and-neck-cancer/340768.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",17,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What therapeutic genome editing strategy does the study propose for HNSCC?","Question",{"text":63,"@type":64},"The study introduces an intratumoral EGFR-targeted CRISPR-LNP strategy to knock out SOX2 using Cas9 mRNA and sgRNA packaged in lipid nanoparticles.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How effective is the approach in vitro?",{"text":68,"@type":64},"LNPs containing ionizable lipids co-encapsulating Cas9 mRNA and sgSOX2 reduce HNSCC cell viability by approximately 60% in vitro.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes are observed in the xenograft mouse model?",{"text":72,"@type":64},"Targeted EGFR-CRISPR-sgSOX2-LNP delivery results in about 90% inhibition of tumor growth and about 90% increased survival for over 84 days, with tumor disappearance in 50% of mice.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340768,1790076805,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","RESEARCH ARTICLE  \n[www.advancedscience.com](www.advancedscience.com)  \nTargeted CRISPR/Cas9 Lipid Nanoparticles Elicits Therapeutic Genome Editing in Head and Neck Cancer  \nRazan Masarwy, Dor Breier, Lior Stotsky-Oterin, Nitay Ad-El, Shahd Qassem,  \nGonna Somu Naidu, Anjaiah Aitha, Assaf Ezra, Meir Goldsmith, Inbal Hazan-Halevy, and Dan Peer*  \nSquamous cell carcinomas ofthe head and neck (HNSCC) originate in the upper aerodigestive tract, including the oral cavity, pharynx, and larynx. Current treatments of locally advanced HNSCC often lead to high treatment failure, and disease recurrence, resulting in poor survival rates. Advances in mRNA technologies and lipid nanoparticle (LNP) delivery systems led to several clinical trials involving LNP-CRISPR-Cas9 mRNA-based therapeutics. Despite these advances, achieving cell-type-speciﬁc extrahepatic mRNA delivery is still challenging. This study introduces a safe and eﬀective intratumoral EGFR-targeted CRISPR-LNP delivery strategy for knocking out SOX2, which is a cancer-speciﬁc gene. To assess their therapeutic potential, it is shown that LNPs made from ionizable lipids with helper lipids  \nco-encapsulating Cas9 mRNA and sgRNA targeting SOX2 (sgSOX2), lead to a ≈60% reduction in HNSCC cell viability in vitro. Next, using a xenograft HNSCC mouse model, targeted delivery of 􀀂EGFR-CRISPR-sgSOX2-LNPs to HNSCC cells resulted in a 90% inhibition of tumor growth and a 90% increase in survival for > 84 days, with tumor disappearance observed in 50% of themice. These ﬁndings emphasize the potential of targeted mRNA-Cas9-LNPs in clinically accessible solid tumors, speciﬁcally in reaching tumor cells and inducing persistent therapeutic responses in tumors with high-recurrence rates like HNSCC.  \nlarynx. [1] It is the sixth most common cancer worldwide, resulting in ≈600000 new cases and 300000 deaths recorded every year.[2] The standard of care for locoregionally advanced HNSCC patients includes either surgical resection combined with adjuvant therapy or deﬁnitive chemoradiotherapy.[3,4] Yet, despite this multimodal therapeutic approach, HNSCC patients suﬀer from high rates of treatment failure, treatment-related toxicities, and disease recurrence which together are responsible for poor survival outcomes. [1]  \nLipid nanoparticles (LNPs) are the most advanced nonviral strategy for efﬁcient in vivo RNA encapsulation and delivery.[5,6] In recent years several projects were started, aiming to harness this platform for CRISPR-Cas9 therapeutics, including oncology, supported by numerous in vivo studies demonstrating the potential of mRNA-Cas9-LNPsin cancer treatment. [7–9] However, the translation of this technology into clinical applications faces various challenges,[10] including challenges inherent to the  \n1. Introduction  \nHead and neck squamous cell carcinomas (HNSCCs) develop from the mucosal epithelium in the oral cavity, pharynx, and  \nCRISPR-Cas9 system itself, the necessity for achieving cell-type-speciﬁc and extrahepatic delivery of themRNA-Cas9-LNPs and the unique characteristics of tumors.  \nR. Masarwy, D. Breier, L. Stotsky-Oterin, N. Ad-El, S. Qassem,  \nG. S. Naidu, A. Aitha, A. Ezra, M. Goldsmith, I. Hazan-Halevy, D. Peer Laboratory of Precision Nanomedicine  \nThe Shmunis School of Biomedicine and Cancer Research George S. Wise Faculty of Life Sciences  \nTel Aviv University  \nTel Aviv 69978, Israel  \nE-mail: [peer@tauex.tau.ac.il](peer@tauex.tau.ac.il)  \nThe ORCID identiﬁcation number(s) for the author(s) of this article  \ncan be found under [https://doi.org/10.1002/advs.202411032](https://doi.org/10.1002/advs.202411032)[ ](https://doi.org/10.1002/advs.202411032)© 2024 The Author(s). Advanced Science published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nDOI: 10.1002/advs.202411032  \nR. Masarwy, D. Breier","cbCaisNr8UJpEE6R","https://ap.wps.com/l/cbCaisNr8UJpEE6R","pdf",3732760,14,"English","# Introduction\n## HNSCC treatment challenges\n## Rationale for mRNA-Cas9 LNPs\n## Need for targeted extrahepatic delivery\n# Tumor microenvironment and delivery barriers\n## Systemic limitations and liver accumulation\n## Intratumoral delivery potential","[{\"question\":\"What therapeutic genome editing strategy does the study propose for HNSCC?\",\"answer\":\"The study introduces an intratumoral EGFR-targeted CRISPR-LNP strategy to knock out SOX2 using Cas9 mRNA and sgRNA packaged in lipid nanoparticles.\"},{\"question\":\"How effective is the approach in vitro?\",\"answer\":\"LNPs containing ionizable lipids co-encapsulating Cas9 mRNA and sgSOX2 reduce HNSCC cell viability by approximately 60% in vitro.\"},{\"question\":\"What outcomes are observed in the xenograft mouse model?\",\"answer\":\"Targeted EGFR-CRISPR-sgSOX2-LNP delivery results in about 90% inhibition of tumor growth and about 90% increased survival for over 84 days, with tumor disappearance in 50% of mice.\"}]","Targeted CRISPR/Cas9 Lipid Nanoparticles Elicits Therapeutic Genome Editing in Head and Neck Cancer | PDF",1790038824,35,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9dcec61226dd675b922e59ec7640a56.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/226d909a19072eca2afbce45cba9ee02.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/753a932cfcc138de3fa9c5e08e2a129e.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a8d9df6958b4ef7a333a4c49fd7b234.webp",980,1287]